Acute Myelogenous Leukemia (AML) Clinical Trials

A listing of Acute Myelogenous Leukemia (AML) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 532 clinical trials
HDM201 and Midostaurin (HDMM) in Relapsed/Refractory AML With FLT3mut and TP53wt.

patients with relapsed/refractory acute myeloid leukemia (AML) with FLT3mut applying an accelerated titration design.

  • 0 views
  • 27 Jan, 2021
  • 1 location
Azacitidine and Homoharringtonine in JMML

, which exhibited a anticancer mechanism and has been widely used in patients with relapse/refractory acute myeloid leukemia (AML). However, the efficacy of these agents has not been elucidated in

myeloid leukemia
azacitidine
refractory acute myeloid leukemia (aml)
  • 0 views
  • 25 Jan, 2021
  • 1 location
Role of the Therapy Tailored to Risk Factors in Treating Adult Patients ( 60) With Acute Myeloid Leukemia

In view of the diversity of the biology of acute myeloid leukemia (AML) therapy in individual patients must be individualized. One of the tools for this is molecular-cytogenetic stratification

cladribine
blast cells
adult acute myelogenous leukemia
filgrastim
decitabine
  • 19 views
  • 08 Nov, 2020
  • 1 location
Study of Magrolimab Combinations in Participants With Myeloid Malignancies

therapies of venetoclax (Ven) and azacitidine (Aza) (Cohort 1), mitoxantrone, etoposide, and cytarabine (MEC) (Cohort 2) and CC-486 (Cohort 3) respectively in participants with acute myeloid leukemia (AML

  • 0 views
  • 07 Jun, 2021
  • 1 location
Study of Azacytidine Combined With Lenalidomide As Maintenance Therapy Based on MRD Monitoring in AML

Great progress has been witnessed on the treatment of acute myeloid leukemia (AML) in recent years. However, elderly patients ineligible for receiving high dose chemotherapy and allo-HSCT, have

  • 0 views
  • 25 Jan, 2021
  • 2 locations
Randomised Prospective Comparison of the NMA Allograft and the Traditional Allograft in Acute Myeloid Leukaemia

acute myeloid leukaemia (AML) of the adult for the patients of less than 55 years, because it offers chances of cure higher than chemotherapy or the auto-graft. However, mortality related to

total body irradiation
secondary acute myeloid leukemia
idarubicin
remission
cyclophosphamide
  • 18 views
  • 07 Nov, 2020
  • 1 location
A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

The purpose of this study is to determine the safety, tolerability, maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of JNJ-74856665 as monotherapy (Arm A) and in combination with azacitidine (AZA) (Arm B).

cell transplantation
human chorionic gonadotropin
myeloid leukemia
azacitidine
refractory acute myeloid leukemia (aml)
  • 0 views
  • 31 May, 2021
  • 26 locations
Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)

The primary objective of this study now is to assess the anti-neoplastic activity of flotetuzumab in patients with PIF/ER AML, as determined by the proportion of patients who achieve complete remission (CR) or complete remission with partial hematologic recovery (CRh).

cytarabine
decitabine
anthracyclines
induction chemotherapy
azacitidine
  • 116 views
  • 03 Jun, 2021
  • 41 locations
INFUSION OF ALLOREACTIVE NATURAL KILLER (NK) CELLS AS CONSOLIDATION STRATEGY FOR ACUTE MYELOID LEUKEMIA PATIENTS

Acute Myeloid Leukemia (AML) patients who had achieved Complete Remission (CR) after (re)induction/consolidation chemotherapy will receive the infusion of alloreactive NK cells. Adult AML

immunosuppressants
cell transplantation
fludarabine
leukapheresis
cyclophosphamide
  • 0 views
  • 03 Feb, 2021
  • 1 location
HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)

This is a phase 1b, multi-arm, open-label study of HDM201 in combination with MBG453 or venetoclax in subjects with AML or high-risk MDS. For all subjects, TP53wt status must be characterized by, at a minimum, no mutations noted in exons 5, 6, 7 and 8. Two treatment arms will enroll …

cell transplantation
cytarabine
TP53
induction chemotherapy
refractory acute myeloid leukemia (aml)
  • 51 views
  • 14 May, 2021
  • 10 locations